By Adriano Marchese
Ocugen's drug to treat retina diseases received a rare pediatric disease designation from U.S. regulators.
The biotechnology said Tuesday that the Food and Drug Administration granted the designation to OCU410ST, a gene therapy for the treatment of ABCA4-associated retinopathies, or genetic retinal disorders.
Previously, OCU410ST received orphan drug designations for the treatment of these retinopathies from the FDA and European Medicines Agency.
With the new designation, Ocugen may be awarded a priority review voucher, if the program is reauthorized by the U.S. Congress, the company said, which is a system designed to encourage drug development for rare diseases.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
May 27, 2025 08:18 ET (12:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.